1. Corporate Officers - S
2. Schilke Tobin

Insider Trading History of Schilke Tobin

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Schilke Tobin since 2017. This trader's CIK number is 1678984. At the time of last reporting, Schilke Tobin was the CFO of Revance Therapeutics, Inc.. (stock ticker symbol RVNC). Also see all insider trading activities at Revance Therapeutics, Inc..

Note that in the past Schilke Tobin also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Achaogen, Inc. (AKAO) by Schilke Tobin

		Insider Buying		Insider Sales		Option Exercises
Year	Symbol	Shares	Value	Shares	Value	Shares	Value
2018	AKAO	0	$0	3,493	$39,618	0	$0
2017	AKAO	0	$0	3,021	$60,504	0	$0

Yearly summary of insider trading at Revance Therapeutics, Inc. (RVNC) by Schilke Tobin

		Insider Buying		Insider Sales		Option Exercises
Year	Symbol	Shares	Value	Shares	Value	Shares	Value
2024	RVNC	0	$0	9,361	$47,207	0	$0
2023	RVNC	0	$0	65,526	$2,123,556	0	$0

Insider trading activities at 2 companies by Schilke Tobin:

1. Achaogen, Inc. (AKAO)

2. Revance Therapeutics, Inc. (RVNC)

Table 1. Insider trading of Achaogen, Inc. (AKAO) by Schilke Tobin

Trade Date	Symbol	Trade Type	Shares	Price ($)	Value ($)
2018-06-26	AKAO	Sale	298	9.59	2,857
2018-06-11	AKAO	Sale	2,087	11.95	24,939
2018-02-21	AKAO	Sale	1,108	10.67	11,822
2017-06-12	AKAO	Sale	2,066	21.53	44,480
2017-01-26	AKAO	Sale	955	16.78	16,024

Table 2. Insider trading of Revance Therapeutics, Inc. (RVNC) by Schilke Tobin

Trade Date	Symbol	Trade Type	Shares	Price ($)	Value ($)
2024-03-18	RVNC	Sale	9,361	5.04	47,207
2023-07-03	RVNC	Sale	1,701	25.04	42,593
2023-06-01	RVNC	Sale	2,701	30.57	82,569
2023-06-02	RVNC	Sale	500	31.00	15,500
2023-05-15	RVNC	Sale	21,401	34.55	739,340
2023-05-01	RVNC	Sale	3,201	31.70	101,471
2023-04-03	RVNC	Sale	3,201	32.15	102,912
2023-04-03	RVNC	Sale	3,201	32.15	102,912
2023-03-09	RVNC	Sale	18,517	31.59	584,877
2023-03-01	RVNC	Sale	3,201	33.50	107,233
2023-02-01	RVNC	Sale	3,201	34.60	110,754
2023-01-20	RVNC	Sale	1,000	31.00	31,000
2023-01-09	RVNC	Sale	3,701	27.67	102,395

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Schilke Tobin (CFO of Revance Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month